Colorectal Cancer

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

Elena Élez, MD, PhD, discusses quality of life outcomes with combination checkpoint blockade in patients with microsatellite instability-high mCRC.

Although clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Tanios S. Bekaii-Saab, MD, discusses sequencing decisions according to molecular subgroups in colorectal cancer.

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.